Combination therapy for advanced HER2-positive cancers
Part of Cancer clinical trials.
This trial tests a new combination of two drugs, BAT8010 and BAT1006, for people with advanced solid tumors that have HER2 expression. It aims to see if this combination is safe and effective for those who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of cancer that tests positive for HER2 (a protein that can help cancer grow) and it is advanced or has spread.
- You have tried standard treatments and they no longer work, or there is no standard treatment for your cancer.
- You are expected to live at least 3 months.
- You are able to care for yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
This trial tests a combination of two experimental drugs, MHB088C and MHB039A, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.